Disclosed herein are hemi-citrate salts of Compound 1, crystalline forms thereof, methods of their preparation, pharmaceutical compositions thereof, and methods of their use.

This disclosure provides formulations of enzalutamide and their use for treating hyperproliferative disorders.

A system for producing pharmaceutical objects, such as tablets, granules and capsules, via 3D printing. The system comprises a 3D printing machine (2) with a mechanical system (3) movable in one or more directions, at least one print head (5) with a nozzle (37) being movable by the mechanical system and a base system (4) carrying a print base (6) for receiving a prepared mixture (27) applied by the print head (5). The system comprises at least one carrier (35) for holding a cartridge (28). Printing is done at formatted print locations (49) on the base (6). A method for producing pharmaceutical objects by providing at least one pharmaceutical substance in at least one cartridge, placing the cartridge in a carrier, establishing a fluid connection between a cartridge and a print head, moving the print head nozzle according to a program and dispensing the pharmaceutical substance to a print base.

A method for preparing a gel product instant-dissolving block includes: adding water into a raw material to dissolve the raw material and carrying out concentrating to obtain a gel solution; carrying out a drying treatment on the gel solution to obtain an irregular cellular gel body; grinding the gel body and carrying out screening to obtain gel powder with a particle size being equal to or larger than 80 meshes; moistening the gel powder with 85 to 95% alcohol and carrying out compression at a compression ratio of 30% to 60% to obtain a block, thereby obtaining the gel product instant-dissolving block. The gel product instant-dissolving block of the present invention has a loose pore structure at the inside, has a high superficial area/volume ratio and has a product density of 0.4 to 0.8 g/cm.sup.3, and is capable of being rapidly dissolved within 2 minutes in hot water.

An ibuprofen controlled-release tablet and a method for preparing same are provided. The controlled-release tablet is composed of a drug-containing immediate-release layer and a drug-containing sustained-release layer, wherein a mass of ibuprofen in the drug-containing sustained-release layer is greater than a mass of ibuprofen in the drug-containing immediate-release layer, and a ratio of the mass of the ibuprofen in the drug-containing sustained-release layer to the mass of the ibuprofen in the drug-containing immediate-release layer is ≤7. The tablet of the present disclosure has an effective analgesic effect for 24 h after administration.

The present invention is directed to the treatment of idiopathic pulmonary fibrosis with (a) a phosphodiesterase 4 inhibitor or (b) a phosphodiesterase 4 inhibitor and a second active pharmaceutical ingredient.

Disclosed is to a new pharmaceutical composition for oral administration containing sulfasalazine and/or a sulfasalazine organic salt, production processes and uses, in particular in the treatment of a disease or condition in which modulation of inflammatory cells is beneficial, a disease or condition concerning bones or joints and/or the gastro-intestinal tract.

An oral product includes a body that is wholly receivable in an oral cavity. The body includes a mouth-stable polymer matrix, cellulosic fibers embedded in the mouth-stable polymer matrix, and an additive dispersed in the mouth-stable polymer matrix. The oral product is adapted to release the additive from the body when the body is received within the oral cavity and exposed to saliva.

The present invention relates to a process for producing a tablet comprising a GLP-1 peptide wherein the GLP-1 peptide is obtained by spray-drying of a feed solution comprising the GLP-1 peptide and a feed solution solvent, wherein the pH of the feed solution is higher that the pI of the GLP-1 peptide or wherein the pH of the feed solution is in the range of about 5 to about 10. The invention also relates to the tablet obtained by said process and the use of said tablet in medicine.

The present invention relates to the use of octenyl succinate starch, in particular sodium octenyl succinate starch as a binder in wet granulation, in particular for pharmaceutical solid dosage form and the granule obtainable by the method thereof.